IMKELDI Drug Patent Profile
✉ Email this page to a colleague
When do Imkeldi patents expire, and when can generic versions of Imkeldi launch?
Imkeldi is a drug marketed by Shorla Oncology and is included in one NDA. There is one patent protecting this drug.
This drug has six patent family members in six countries.
The generic ingredient in IMKELDI is imatinib mesylate. There are thirty-four drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Imkeldi
A generic version of IMKELDI was approved as imatinib mesylate by TEVA PHARMS USA on August 4th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IMKELDI?
- What are the global sales for IMKELDI?
- What is Average Wholesale Price for IMKELDI?
Summary for IMKELDI
| International Patents: | 6 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 328 |
| What excipients (inactive ingredients) are in IMKELDI? | IMKELDI excipients list |
| DailyMed Link: | IMKELDI at DailyMed |
Pharmacology for IMKELDI
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Bcr-Abl Tyrosine Kinase Inhibitors Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inhibitors |
US Patents and Regulatory Information for IMKELDI
IMKELDI is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shorla Oncology | IMKELDI | imatinib mesylate | SOLUTION;ORAL | 219097-001 | Nov 22, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IMKELDI
See the table below for patents covering IMKELDI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2018306149 | ⤷ Start Trial | |
| China | 111278466 | ⤷ Start Trial | |
| European Patent Office | 3658190 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IMKELDI
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0564409 | C00564409/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IMATINIB; REGISTRATION NO/DATE: IKS 55807 20010621 |
| 0564409 | SPC/GB02/016 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108 |
| 0564409 | C300086 | Netherlands | ⤷ Start Trial | PRODUCT NAME: IMATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESILAAT; NATL. REGISTRATION NO/DATE: EU/1/01/198/001 - 006 20011107; FIRST REGISTRATION: CH IKS 55807 20010621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch